Nanomedicine in central nervous system (CNS) disorders: A present and future prospective

Advanced Pharmaceutical Bulletin

Volumn 6, Issue 3, 2016, Pages 319-335

  Soni, Shringika ^a   Ruhela, Rakesh Kumar ^a   Medhi, Bikash ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Blood brain barrier; CNS therapeutics; Drug delivery; Nanocarrier; Nanomedicine; Nanotechnology

Indexed keywords

AMPHOTERICIN B; ATAZANAVIR; CARBON NANOTUBE; CERIUM OXIDE NANOPARTICLE; CYANOACRYLATE DERIVATIVE; DAUNORUBICIN; DENDRIMER; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FLOXURIDINE 3',5' DIOCTANOATE; FULLERENE; GLIAL FIBRILLARY ACIDIC PROTEIN; GOLD NANOPARTICLE; HEAT SHOCK PROTEIN; MACROGOL; MULTI WALLED NANOTUBE; NERVE GROWTH FACTOR; PACLITAXEL; POLYAMIDOAMINE; POLYGLUTAMIC ACID; POLYPROPYLENE; POLYSORBATE 80; PREDNISOLONE; QUINOLONE DERIVATIVE; SINGLE WALLED NANOTUBE; SOLID LIPID NANOPARTICLE; STREPTAVIDIN; THIOFLAVINE; UNINDEXED DRUG; VINCRISTINE SULFATE;

ALLERGIC ENCEPHALITIS; ALZHEIMER DISEASE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEM; EPILEPSY; GENE THERAPY; GLIOBLASTOMA; HIV ASSOCIATED DEMENTIA; HUMAN; LIPOPHILICITY; MATERIAL COATING; MICELLE; MULTIPLE SCLEROSIS; NANOBIOTECHNOLOGY; NANOENCAPSULATION; NANOMEDICINE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; REVIEW; SYSTEMATIC REVIEW;

EID: 84995578310     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2016.044     Document Type: Review

References (201)

1. Spuch C, Saida O, Navarro C. Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles. Recent Pat Drug Deliv Formul 2012;6(1):2-18
2. Hyman S, Chisholm D, Kessler R, Petal V, Whiteford H. Mental Disorders. In: Jamsion DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. P. 605-25
3. Domínguez A, Álvarez A, Hilario E, Suarez-Merino B, Goñi-de-Cerio F. Central nervous system diseases and the role of the blood-brain barrier in their treatment. Neurosci Discov 2013;1(3):1-11. doi: 10.7243/2052-6946-1-3
4. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57(3):418-20. doi: 10.1001/archneur.57.3.418
5. Whiting PJ. GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery? Drug Discov Today 2003;8(10):445-50. doi: 10.1016/S1359-6446(03)02703-X
6. Alguacil LF, Perez-Garcia C. Histamine H3 receptor: a potential drug target for the treatment of central nervous system disorders. Curr Drug Targets CNS Neurol Disord 2003;2(5):303-13. doi: 10.2174/1568007033482760
7. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008;117(2):232-43. doi: 10.1016/j.pharmthera.2007.09.009
8. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997;33(6):454-71. doi: 10.2165/00003088-199733060-00004
9. Jain KK. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis 2007;4(4):287-91. doi: 10.1159/000101884
10. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012;64(7):686-700. doi: 10.1016/j.addr.2011.10.007
11. Domínguez A, Álvarez A, Suárez-Merino B, Goñi-de-Cerio F. Neurological disorders and the blood-brain barrier. Strategies and limitations for drug delivery to the brain. Rev Neurol 2014;58(5):213-24
12. Pardridge WM. Strategies for Drug Delivery through the Blood-Brain Barrier. In: Borchardt RT, Repta AJ, Stella VJ, editors. Directed Drug Delivery: A Multidisciplinary Approach. Clifton, NJ: Humana Press; 1985. P. 83-96
13. Tamai I, Tsuji A. Drug delivery through the blood-brain barrier. Adv Drug Deliv Rev 1996;19(3):401-24. doi: 10.1016/0169-409X(96)00011-7
14. Tajes M, Ramos-Fernández E, Weng-Jiang X, Bosch-Morató M, Guivernau B, Eraso-Pichot A, et al. The blood-brain barrier: Structure, function and therapeutic approaches to cross it. Mol Membr Biol 2014;31(5):152-67. doi: 10.3109/09687688.2014.937468
15. Stockwell J, Abdi N, Lu X, Maheshwari O, Taghibiglou C. Novel central nervous system drug delivery systems. Chem Biol Drug Des 2014;83(5):507-20. doi: 10.1111/cbdd.12268
16. Yi X, Manickam DS, Brynskikh A, Kabanov AV. Agile delivery of protein therapeutics to CNS. J Control Release 2014;190:637-63. doi: 10.1016/j.jconrel.2014.06.017
17. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40(5):385-403. doi: 10.1016/j.ejps.2010.05.003
18. Halberstadt C, Emerich DF, Gonsalves K. Combining cell therapy and nanotechnology. Expert Opin Biol Ther 2006;6(10):971-81. doi: 10.1517/14712598.6.10.971
19. Emerich DF, Orive G, Borlongan C. Tales of biomaterials, molecules, and cells for repairing and treating brain dysfunction. Curr Stem Cell Res Ther 2011;6(3):171-89. doi: 10.2174/157488811796575350
20. Aliautdin RN, Kreuter J, Kharkevich DA. Drug delivery to the brain with nanoparticles. Eksp Klin Farmakol 2003;66(2):65-8
21. Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol 2005;63(4):301-6. doi: 10.1016/j.surneu.2004.06.008
22. Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009;10(9):682-92. doi: 10.1038/nrn2685
23. Hwang JY, Shin US, Jang WC, Hyun JK, Wall IB, Kim HW. Biofunctionalized carbon nanotubes in neural regeneration: a mini-review. Nanoscale 2013;5(2):487-97. doi: 10.1039/c2nr31581e
24. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-92
25. Segal E, Satchi-Fainaro R. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 2009;61(13):1159-76. doi: 10.1016/j.addr.2009.06.005
26. Chen YW, Hwang KC, Yen CC, Lai YL. Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. Am J Physiol Regul Integr Comp Physiol 2004;287(1):R21-6. doi: 10.1152/ajpregu.00310.2003
27. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17(7):713-31. doi: 10.1097/00004647-199707000-00001
28. Pathan SA, Iqbal Z, Zaidi SM, Talegaonkar S, Vohra D, Jain GK, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009;3(1):71-89. doi: 10.2174/187221109787158355
29. Crone C. The blood-brain barrier: a modified tight epithelium. In: Suckling AJ, Rumsby MG, Bradbury MWB, editors. The blood-brain barrier in health and disease. Chichester: Ellis Horwood Ltd; 1986. P. 17-40
30. Upadhyay RK. Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier. Biomed Res Int 2014;2014:869269. doi: 10.1155/2014/869269
31. Stenehjem DD, Hartz AM, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med Chem 2009;1(9):1623-41. doi: 10.4155/fmc.09.137
32. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37(1):48-57. doi: 10.1016/j.nbd.2009.07.028
33. Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994;14(5):862-70. doi: 10.1038/jcbfm.1994.108
34. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9(9):1580-90
35. Rapoport SI. Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20(2):217-30
36. Erdlenbruch B, Schinkhof C, Kugler W, Heinemann DE, Herms J, Eibl H, et al. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol 2003;139(4):685-94. doi: 10.1038/sj.bjp.0705302
37. Lee HJ, Park J, Yoon OJ, Kim HW, Lee DY, Kim do H, et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat Nanotechnol 2011;6(2):121-5. doi: 10.1038/nnano.2010.281
38. Aird RB. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol 1984;86(2):342-58. doi: 10.1016/0014-4886(84)90192-4
39. Zhang Y, Miller DW. Pathways for drug delivery to the Central nervous system. In: Wang B, Siahaan TJ, Soltero R, editors. Drug delivery: Principles and applications. New Jersey: John Wiley and Sons; 2005. P. 29-56
40. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26. doi: 10.1016/S0169-409X(00)00129-0
41. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998;70(5):1781-92. doi: 10.1046/j.1471-4159.1998.70051781.x
42. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013;65(1):36-48. doi: 10.1016/j.addr.2012.09.037
43. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009;88(4):272-85. doi: 10.1016/j.pneurobio.2009.05.002
44. Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part 1: Background and applications. Trop J Pharm Res 2009;8(3):265-74. doi: 10.4314/tjpr.v8i3.44546
45. Dinda SC, Pattnaik G. Nanobiotechnology-based drug delivery in brain targeting. Curr Pharm Biotechnol 2013;14(15):1264-74. doi: 10.2174/1389201015666140608143719
46. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997;14(11):1568-73. doi: 10.1023/A:1012126301290
47. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 2004;4(5):484-8. doi: 10.1166/jnn.2003.077
48. Mohanraj K, Sethuraman S, Krishnan UM. Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of parkinson's disease. J Biomed Mater Res B Appl Biomater 2013;101(5):840-7. doi: 10.1002/jbm.b.32888
49. Miller G. Drug targeting. Breaking down barriers. Science 2002;297(5584):1116-8. doi: 10.1126/science.297.5584.1116
50. Khanbabaie R, Jahanshahi M. Revolutionary impact of nanodrug delivery on neuroscience. Curr Neuropharmacol 2012;10(4):370-92. doi: 10.2174/157015912804143513
51. Haque S, Md S, Intekhab Alam M, Kaur Sahni J, Ali J, Baboota S. Nanomedicines for brain targeting: A patent review. Recent Pat Nanomed 2011;1(2):149-61. doi: 10.2174/1877912311101020149
52. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: Studies with fractionated nanoparticles. Int J Pharm 2002;244(1-2):105-15
53. Caldorera-Moore M, Peppas NA. Micro-and nanotechnologies for intelligent and responsive biomaterial-based medical systems. Adv Drug Deliv Rev 2009;61(15):1391-401. doi: 10.1016/j.addr.2009.09.002
54. Jain N, Jain R, Thakur N, Gupta BP, Jain DK, Banveer J, et al. Nanotechnology: A safe and effective drug delivery system. Asian J Pharm Clin Res 2010;3(3):159-65
55. Liu Q, Cao X, Wang T, Wang C, Zhang Q, Ma L. Synthesis of shape-controllable cobalt nanoparticles and their shape-dependent performance in glycerol hydrogenolysis. RSC Adv 2015;5(7):4861-71. doi: 10.1039/c4ra13395a
56. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011;5(5):3679-92. doi: 10.1021/nn200007z
57. Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci 2012;368(1):144-51. doi: 10.1016/j.jcis.2011.11.024
58. Labala S, Mandapalli PK, Kurumaddali A, Venuganti VV. Layer-by-Layer Polymer Coated Gold Nanoparticles for Topical Delivery of Imatinib Mesylate To Treat Melanoma. Mol Pharm 2015;12(3):878-88. doi: 10.1021/mp5007163
59. Chen Z, Zhang L, Song Y, He J, Wu L, Zhao C, et al. Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery. Biomaterials 2015;52:240-50. doi: 10.1016/j.biomaterials.2015.02.001
60. Discher DE, Eisenberg A. Polymer vesicles. Science 2002;297(5583):967-73. doi: 10.1126/science.1074972
61. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 2012;17(7-8):367-78. doi: 10.1016/j.drudis.2011.10.028
62. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8(2):147-66. doi: 10.1016/j.nano.2011.05.016
63. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009;17(8):2950-62. doi: 10.1016/j.bmc.2009.02.043
64. Banks WA, Kastin AJ, Barrera CM. Delivering peptides to the central nervous system: dilemmas and strategies. Pharm Res 1991;8(11):1345-50. doi: 10.1023/A:1015884603456
65. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005;108(2-3):193-214. doi: 10.1016/j.jconrel.2005.07.024
66. Bronich TK, Bontha S, Shlyakhtenko LS, Bromberg L, Hatton TA, Kabanov AV. Template-assisted synthesis of nanogels from Pluronic-modified poly(acrylic acid). J Drug Target 2006;14(6):357-66. doi: 10.1080/10611860600833781
67. Friedrich I, Reichl S, Muller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm 2005;305(1-2):167-75. doi: 10.1016/j.ijpharm.2005.09.007
68. Dikpati A, Madgulkar AR, Kshirsagar SJ, Bhalekar MR, Singh Chahal A. Targeted Drug Delivery to CNS using Nanoparticles. J Adv Pharm Sci 2012;2(1):179-91
69. Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003;24(10):1781-5. doi: 10.1016/S0142-9612(02)00578-1
70. Saupe A, Rades T. Solid Lipid Nanoparticles. In: Mozafari MR, editor. Solid Lipid Nanoparticles. Frontiers of Nanotherapy. Dordrecht, Netherlands: Springer; 2006. P. 41-50
71. Onoue S, Yamada S, Chan HK. Nanodrugs: Pharmacokinetics and safety. Int J Nanomedicine 2014;9:1025-37. doi: 10.2147/IJN.S38378
72. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 2008;25(7):1521-30. doi: 10.1007/s11095-007-9514-y
73. McClements DJ, Decker EA, Weiss J. Emulsion-based delivery systems for lipophilic bioactive components. J Food Sci 2007;72(8):R109-24. doi: 10.1111/j.1750-3841.2007.00507.x
74. Rodríguez-Gascón A, del Pozo-Rodríguez A, Solinís Má. Development of nucleic acid vaccines: Use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine 2014;9:1833-43. doi: 10.2147/IJN.S39810
75. Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011;63(3):342-51. doi: 10.1111/j.2042-7158.2010.01225.x
76. Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002;10(5):387-96. doi: 10.1080/1061186021000001832
77. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3', 5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002;54(3):285-90. doi: 10.1016/S0939-6411(02)00083-8
78. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008;25(10):2262-71. doi: 10.1007/s11095-008-9615-2
79. Cheng Y, Wang J, Rao T, He X, Xu T. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci 2008;13:1447-71. doi: 10.2741/2774
80. Safari J, Zarnegar Z. Advanced drug delivery systems: Nanotechnology of health design A review. J Saudi Chem Soc 2014;18(2):85-99. doi: 10.1016/j.jscs.2012.12.009
81. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003;257(1-2):111-24. doi: 10.1016/S0378-5173(03)00132-7
82. Martinho N, Florindo H, Silva L, Brocchini S, Zloh M, Barata T. Molecular modeling to study dendrimers for biomedical applications. Molecules 2014;19(12):20424-67. doi: 10.3390/molecules191220424
83. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005;57(15):2215-37. doi: 10.1016/j.addr.2005.09.019
84. Pan S, Wang C, Zeng X, Wen Y, Wu H, Feng M. Short multi-armed polylysine-graft-polyamidoamine copolymer as efficient gene vectors. Int J Pharm 2011;420(2):206-15. doi: 10.1016/j.ijpharm.2011.08.036
85. Boridy S, Soliman GM, Maysinger D. Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. Nanomedicine (Lond) 2012;7(8):1149-65. doi: 10.2217/nnm.12.16
86. Cerqueira SR, Silva BL, Oliveira JM, Mano JF, Sousa N, Salgado AJ, et al. Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells. Macromol Biosci 2012;12(5):591-7. doi: 10.1002/mabi.201100294
87. Beg S, Samad A, Alam MI, Nazish I. Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. CNS Neurol Disord Drug Targets 2011;10(5):576-88. doi: 10.2174/187152711796235023
88. Bilia AR, Guccione C, Isacchi B, Righeschi C, Firenzuoli F, Bergonzi MC. Essential oils loaded in nanosystems: A developing strategy for a successful therapeutic approach. Evid Based Complement Alternat Med 2014;2014:651593. doi: 10.1155/2014/651593
89. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: Relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 2012;160(2):281-9. doi: 10.1016/j.jconrel.2011.10.003
90. Bawa R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnol Law Bus 2008;5(2):135-55
91. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000;39(2):207-11. doi: 10.1080/028418600430789
92. Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003;51(9):1241-4. doi: 10.1177/002215540305100915
93. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996;93(24):14164-9. doi: 10.1073/pnas.93.24.14164
94. Ramos-Cabrer P, Campos F, Sobrino T, Castillo J. Targeting the ischemic penumbra. Stroke 2011;42(1 Suppl):S7-11. doi: 10.1161/STROKEAHA.110.596684
95. Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, et al. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials 2015;39:23-30. doi: 10.1016/j.biomaterials.2014.10.069
96. Mohamed S, Parayath NN, Taurin S, Greish K. Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Ther Deliv 2014;5(10):1101-21. doi: 10.4155/tde.14.69
97. Butun S, Ince FG, Erdugan H, Sahiner N. One-step fabrication of biocompatible carboxymethyl cellulose polymeric particles for drug delivery systems. Carbohydr Polym 2011;86(2):636-43. doi: 10.1016/j.carbpol.2011.05.001
98. Akimoto J, Nakayama M, Okano T. Temperature-responsive polymeric micelles for optimizing drug targeting to solid tumors. J Control Release 2014;193:2-8. doi: 10.1016/j.jconrel.2014.06.062
99. Zhao BX, Zhao Y, Huang Y, Luo LM, Song P, Wang X, et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012;33(8):2508-20. doi: 10.1016/j.biomaterials.2011.11.078
100. Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Deliv Rev 2013;65(5):663-76. doi: 10.1016/j.addr.2012.05.004
101. Sahoo NG, Rana S, Cho JW, Li L, Chan SH. Polymer nanocomposites based on functionalized carbon nanotubes. Prog Polym Sci 2010:35(7):837-67. doi: 10.1016/j.progpolymsci.2010.03.002
102. Tran PA, Zhang L, Webster TJ. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv Drug Deliv Rev 2009;61(12):1097-114. doi: 10.1016/j.addr.2009.07.010
103. Dyke CA, Tour JM. Overcoming the insolubility of carbon nanotubes through high degrees of sidewall functionalization. Chemistry 2004;10(4):812-7. doi: 10.1002/chem.200305534
104. Zeineldin R, Al-Haik M, Hudson LG. Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells. Nano Lett 2009;9(2):751-7. doi: 10.1021/nl8033174
105. Yang Z, Zhang Y, Yang Y, Sun L, Han D, Li H, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating alzheimer disease. Nanomedicine 2010;6(3):427-41. doi: 10.1016/j.nano.2009.11.007
106. Moon SU, Kim J, Bokara KK, Kim JY, Khang D, Webster TJ, et al. Carbon nanotubes impregnated with subventricular zone neural progenitor cells promotes recovery from stroke. Int J Nanomedicine 2012;7:2751-65. doi: 10.2147/IJN.S30273
107. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, et al. Targeted delivery of amphotericin b to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl 2005;44(39):6358-62. doi: 10.1002/anie.200501613
108. Passeri D, Rinaldi F, Ingallina C, Carafa M, Rossi M, Terranova ML, et al. Biomedical applications of nanodiamonds: An overview. J Nanosci Nanotechnol 2015;15(2):972-88
109. Nielsen GD, Roursgaard M, Jensen KA, Poulsen SS, Larsen ST. In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol 2008;103(3):197-208. doi: 10.1111/j.1742-7843.2008.00266.x
110. Anilkumar P, Lu F, Cao L, Luo PG, Liu JH, Sahu S, et al. Fullerenes for applications in biology and medicine. Curr Med Chem 2011;18(14):2045-59
111. Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci 2010;114(2):162-82. doi: 10.1093/toxsci/kfp265
112. Tykhomyrov AA, Nedzvetsky VS, Klochkov VK, Andrievsky GV. Nanostructures of hydrated c60 fullerene (c60hyfn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals. Toxicology 2008;246(2-3):158-65. doi: 10.1016/j.tox.2008.01.005
113. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47(1):65-81
114. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 2001;9(3):209-21
115. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, et al. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 2000;12(6):1931-40
116. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999;291(3):1017-22
117. Hwang SR, Kim K. Nano-enabled delivery systems across the blood-brain barrier. Arch Pharm Res 2014;37(1):24-30. doi: 10.1007/s12272-013-0272-6
118. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009;461(7266):895-7. doi: 10.1038/461895a
119. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu Rev Public Health 2002;23:213-31. doi: 10.1146/annurev.publhealth.23.100901.140525
120. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A delphi consensus study. Lancet 2005;366(9503):2112-7. doi: 10.1016/S0140-6736(05)67889-0
121. Drolle E, Hane F, Lee B, Leonenko Z. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in alzheimer's disease. Drug Metab Rev 2014;46(2):207-23. doi: 10.3109/03602532.2014.882354
122. Munoz DG, Feldman H. Causes of alzheimer's disease. CMAJ 2000;162(1):65-72
123. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in alzheimer's disease. J Neurosci 2001;21(9):3017-23
124. Hashimoto K, Fukushima T, Shimizu E, Okada S, Komatsu N, Okamura N, et al. Possible role of d-serine in the pathophysiology of alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(2):385-8
125. Fazil M, Shadab, Baboota S, Sahni JK, Ali J. Nanotherapeutics for alzheimer's disease (ad): Past, present and future. J Drug Target 2012;20(2):97-113. doi: 10.3109/1061186X.2011.607499
126. Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano 2014;8(3):1958-65. doi: 10.1021/nn501292z
127. D'Angelo B, Santucci S, Benedetti E, Di Loreto S, Phani RA, Falone S, et al. Cerium Oxide nanoparticles trigger neuronal survival in a human Alzheimer disease model by modulating BDNF pathway. Curr Nanosci 2009;5(2):167-76. doi: 10.2174/157341309788185523
128. Picone P, Bondi ML, Montana G, Bruno A, Pitarresi G, Giammona G, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles. Free Radic Res 2009;43(11):1133-45
129. Carroll RT, Bhatia D, Geldenhuys W, Bhatia R, Miladore N, Bishayee A, et al. Brain-targeted delivery of tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010;18(9):665-74. doi: 10.3109/10611861003639796
130. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (egcg) for the treatment of alzheimer's disease. Int J Pharm 2010;389(1-2):207-12. doi: 10.1016/j.ijpharm.2010.01.012
131. Giordano C, Albani D, Gloria A, Tunesi M, Rodilossi S, Russo T, et al. Nanocomposites for neurodegenerative diseases: Hydrogel-nanoparticle combinations for a challenging drug delivery. Int J Artif Organs 2011;34(12):1115-27. doi: 10.5301/IJAO.2011.8915
132. Hartig W, Paulke BR, Varga C, Seeger J, Harkany T, Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-t after intrahippocampal injection in mouse: Implications for targeting beta-amyloid in alzheimer's disease. Neurosci Lett 2003;338(2):174-6
133. Cui D, Gao H. Advance and prospect of bionanomaterials. Biotechnol Prog 2003;19(3):683-92. doi: 10.1021/bp025791i
134. Herholz K. Acetylcholine esterase activity in mild cognitive impairment and alzheimer's disease. Eur J Nucl Med Mol Imaging 2008;35 Suppl 1:S25-9. doi: 10.1007/s00259-007-0699-4
135. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in alzheimer's disease Tg2576 mice. AAPS J 2013;15(2):324-36. doi: 10.1208/s12248-012-9444-4
136. Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res 2010;62(2):166-78. doi: 10.1016/j.phrs.2010.02.004
137. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03
138. Singh N, Pillay V, Choonara YE. Advances in the treatment of parkinson's disease. Prog Neurobiol 2007;81(1):29-44. doi: 10.1016/j.pneurobio.2006.11.009
139. Moore RY. Organization of midbrain dopamine systems and the pathophysiology of parkinson's disease. Parkinsonism Relat Disord 2003;9 Suppl 2:S65-71
140. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of parkinson's disease. Annu Rev Neurosci 2005;28:57-87. doi: 10.1146/annurev.neuro.28.061604.135718
141. Lewitt PA. Levodopa for the treatment of parkinson's disease. N Engl J Med 2008;359(23):2468-76. doi: 10.1056/NEJMct0800326
142. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12(1-2):54-61. doi: 10.1016/j.drudis.2006.10.013
143. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009;17(8):564-74. doi: 10.1080/10611860903112842
144. Khasnavis S, Ghosh A, Roy A, Pahan K. Castration induces parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem 2013;288(29):20843-55. doi: 10.1074/jbc.M112.443556
145. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated peg-plga nanoparticles for brain delivery: Preparation, characterization and efficacy in parkinson's disease. Int J Pharm 2011;415(1-2):273-83. doi: 10.1016/j.ijpharm.2011.05.062
146. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012;379(9830):1984-96. doi: 10.1016/S0140-6736(11)61346-9
147. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: The national survey of intracranial neoplasms. Neurology 1985;35(2):219-26
148. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro Oncol 2002;4(4):278-99
149. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6(3):539-46. doi: 10.1016/j.nurt.2009.04.004
150. Zhan C, Lu W. The blood-brain/tumor barriers: Challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol 2012;13(12):2380-7
151. Lee P, Zhang R, Li V, Liu X, Sun RW, Che CM, et al. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine 2012;7:731-7. doi: 10.2147/IJN.S28783
152. Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 2005;4(4):407-16. doi: 10.1177/153303460500400408
153. Xi G, Robinson E, Mania-Farnell B, Vanin EF, Shim KW, Takao T, et al. Convection-enhanced delivery of nanodiamond drug delivery platforms for intracranial tumor treatment. Nanomedicine 2014;10(2):381-91. doi: 10.1016/j.nano.2013.07.013
154. Kateb B, Van Handel M, Zhang L, Bronikowski MJ, Manohara H, Badie B. Internalization of mwcnts by microglia: Possible application in immunotherapy of brain tumors. NeuroImage 2007;37 Suppl 1:S9-17. doi: 10.1016/j.neuroimage.2007.03.078
155. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65(12):5317-24. doi: 10.1158/0008-5472.CAN-04-392
156. Yinghuai Z, Hosmane NS. Applications and perspectives of boron-enriched nanocomposites in cancer therapy. Future Med Chem 2013;5(6):705-14. doi: 10.4155/fmc.13.47
157. Shapshak P, Chiappelli F, Commins D, Singer E, Levine AJ, Somboonwit C, et al. Molecular epigenetics, chromatin, and NeuroAIDS/HIV: translational implications. Bioinformation 2008;3(1):53-7. doi: 10.6026/97320630003053
158. Mintz M. Clinical comparison of adult and pediatric NeuroAIDS. Adv Neuroimmunol 1994;4(3):207-21. doi: 10.1016/S0960-5428(06)80259-7
159. Bloom FE, Rausch DM. HIV in the brain: pathology and neurobehavioral consequences. J Neurovirol 1997;3(2):102-9. doi: 10.3109/13550289709015800
160. Banks WA, Ercal N, Price TO. The blood-brain barrier in neuroAIDS. Curr HIV Res 2006;4(3):259-66. doi: 10.2174/157016206777709447
161. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, Taffe MA, et al. Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. Am J Pathol 2003;162(6):2041-57. doi: 10.1016/S0002-9440(10)64336-2
162. Doualla-Bell F, Turner D, Loemba H, Petrella M, Brenner B, Wainberg MA. HIV drug resistance and optimization of antiviral treatment in resource-poor countries. Med Sci (Paris) 2004;20(10):882-6. doi: 10.1051/medsci/20042010882
163. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006;108(8):2827-35. doi: 10.1182/blood-2006-03-012534
164. Sagar V, Pilakka-Kanthikeel S, Pottathil R, Saxena SK, Nair M. Towards nanomedicines for neuroAIDS. Rev Med Virol 2014;24(2):103-24. doi: 10.1002/rmv.1778
165. Omar RF, Dusserre N, Desormeaux A, Poulin L, Tremblay M, Beauchamp D, et al. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995;39(9):1973-8. doi: 10.1128/AAC.39.9.1973
166. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007;340(1-2):143-52. doi: 10.1016/j.ijpharm.2007.03.012
167. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006;37(2):345-50. doi: 10.1161/01.STR.0000199613.38911.b2
168. Shcharbina N, Shcharbin D, Bryszewska M. Nanomaterials in stroke treatment: perspectives. Stroke 2013;44(8):2351-5. doi: 10.1161/STROKEAHA.113.001298
169. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009;4(6):461-70. doi: 10.1111/j.1747-4949.2009.00387.x
170. Martin HG, Wang YT. Blocking the Deadly Effects of the NMDA Receptor in Stroke. Cell 2010;140(2):174-6. doi: 10.1016/j.cell.2010.01.014
171. Weiss N, Miller F, Cazaubon S, Couraud PO. Blood-brain barrier part III: therapeutic approaches to cross the blood-brain barrier and target the brain. Rev Neurol (Paris) 2010;166(3):284-8. doi: 10.1016/j.neurol.2009.06.005
172. Mdzinarishvili A, Sutariya V, Talasila PK, Geldenhuys WJ, Sadana P. Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res 2013;3(4):309-17. doi: 10.1007/s13346-012-0117-8
173. Estevez AY, Pritchard S, Harper K, Aston JW, Lynch A, Lucky JJ, et al. Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radic Biol Med 2011;51(6):1155-63. doi: 10.1016/j.freeradbiomed.2011.06.006
174. Takamiya M, Miyamoto Y, Yamashita T, Deguchi K, Ohta Y, Abe K. Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke-and tissue plasminogen activator-related brain damages in mice. Neuroscience 2012;221:47-55. doi: 10.1016/j.neuroscience.2012.06.060
175. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009;29(44):13761-9. doi: 10.1523/JNEUROSCI.4246-09.2009
176. Zhao H, Bao XJ, Wang RZ, Li GL, Gao J, Ma SH, et al. Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats. Hum Gene Ther 2011;22(2):207-15. doi: 10.1089/hum.2010.111
177. Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 2002;44(5):309-16. doi: 10.1111/j.1469-8749.2002.tb00816.x
178. Li MH, Choi SK, Thomas TP, Desai A, Lee KH, Kotlyar A, et al. Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting. Eur J Med Chem 2012;47(1):560-72. doi: 10.1016/j.ejmech.2011.11.027
179. Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil 2006;28(4):183-91. doi: 10.1080/09638280500158422
180. Arneson CL, Durkin MS, Benedict RE, Kirby RS, Yeargin-Allsopp M, Van Naarden Braun K, et al. Prevalence of cerebral palsy: Autism and Developmental Disabilities Monitoring Network, three sites, United States, 2004. Disabil Health J 2009;2(1):45-8. doi: 10.1016/j.dhjo.2008.08.001
181. Robinson KG, Mendonca JL, Militar JL, Theroux MC, Dabney KW, Shah SA, et al. Disruption of basal lamina components in neuromotor synapses of children with spastic quadriplegic cerebral palsy. PLoS One 2013;8(8):e70288. doi: 10.1371/journal.pone.0070288
182. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 2012;4(130):130ra46. doi: 10.1126/scitranslmed.3003162
183. Huang DM, Chung TH, Hung Y, Lu F, Wu SH, Mou CY, et al. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. Toxicol Appl Pharmacol 2008;231(2):208-15. doi: 10.1016/j.taap.2008.04.009
184. Senanayake N, Roman GC. Epidemiology of epilepsy in developing countries. Bull World Health Organ 1993;71(2):247-58
185. Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40(5):631-6. doi: 10.1111/j.1528-1157.1999.tb05566.x
186. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, Van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-85. doi: 10.1111/j.1528-1167.2010.02522.x
187. Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008;22(6):797-803. doi: 10.1016/j.bbi.2008.03.009
188. Lee HS, Wang SY, Salter DM, Wang CC, Chen SJ, Fan HC. The impact of the use of antiepileptic drugs on the growth of children. BMC Pediatr 2013;13:211. doi: 10.1186/1471-2431-13-211
189. Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine 2011;6:363-71. doi: 10.2147/IJN.S15881
190. Samia O, Hanan R, Kamal el T. Carbamazepine mucoadhesive nanoemulgel (MNEG) as brain targeting delivery system via the olfactory mucosa. Drug Deliv 2012;19(1):58-67. doi: 10.3109/10717544.2011.644349
191. Yusuf M, Khan RA, Khan M, Ahmed B. Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β-carotene nanoparticles. Int J Nanomedicine 2012;7:4311-21. doi: 10.2147/IJN.S34588
192. Bradford CM, Ramos I, Cross AK, Haddock G, McQuaid S, Nicholas AP, et al. Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis. J Neuroimmunol 2014;273(1-2):85-95. doi: 10.1016/j.jneuroim.2014.05.007
193. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, et al. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res 2014;2014:961863. doi: 10.1155/2014/961863
194. Heckman KL, Decoteau W, Estevez A, Reed KJ, Costanzo W, Sanford D, et al. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. ACS Nano 2013;7(12):10582-96. doi: 10.1021/nn403743b
195. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS. Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals. CNS Neurol Disord Drug Targets 2012;11(1):40-9. doi: 10.2174/187152712799960781
196. Sharma HS, Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog Brain Res 2007;162:245-73. doi: 10.1016/S0079-6123(06)62013-X
197. Sharma HS, Ali SF, Tian ZR, Hussain SM, Schlager JJ, Sjöquist PO, et al. Chronic treatment with nanoparticles exacerbate hyperthermia induced blood-brain barrier breakdown, cognitive dysfunction and brain pathology in the rat. Neuroprotective effects of nanowired-antioxidant compound H-290/51. J Nanosci Nanotechnol 2009;9(8):5073-90. doi: 10.1166/jnn.2009.gr10
198. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127(2):97-109. doi: 10.1016/j.jconrel.2007.12.018
199. Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 2008;60(8):929-38. doi: 10.1016/j.addr.2007.11.007
200. Krol S. Challenges in drug delivery to the brain: Nature is against us. J Control Release 2012;164(2):145-55. doi: 10.1016/j.jconrel.2012.04.044
201. Gloria A, De Santis R, Ambrosio L, Causa F, Tanner KE. A multi-component fiber-reinforced PHEMA-based hydrogel/HAPEXTM device for customized intervertebral disc prosthesis. J Biomater Appl 2011;25(8):795-810. doi: 10.1177/088532820936093